Published in Transl Gastrointest Cancer on February 08, 2012
HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells. PLoS Pathog (2014) 0.88
Laparoscopic versus open resection of gastric gastrointestinal stromal tumors. Chin J Cancer Res (2013) 0.88
Characterization of gastric and neuronal histaminergic populations using a transgenic mouse model. PLoS One (2013) 0.82
microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway. Clin Exp Med (2014) 0.82
Clinicopathological feature and prognosis of primary hepatic gastrointestinal stromal tumor. Cancer Med (2016) 0.77
Vam3, a Compound Derived from Vitis amurensis Rupr., Attenuated Colitis-Related Tumorigenesis by Inhibiting NF-κB Signaling Pathway. Front Pharmacol (2016) 0.75
Hepatocellular carcinoma. Lancet (2003) 22.54
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
Inflammation and colon cancer. Gastroenterology (2010) 6.32
Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science (2002) 5.82
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature (1996) 5.48
Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 5.12
The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell (1990) 4.91
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Critical protective role of mast cells in a model of acute septic peritonitis. Nature (1996) 4.71
Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell (1990) 3.98
Angiogenesis and tumor metastasis. Annu Rev Med (1998) 3.08
IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol (2010) 3.04
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Inflammation and the development of pancreatic cancer. Surg Oncol (2002) 2.83
Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem (2007) 2.81
Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A (2005) 2.59
Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology (2005) 2.56
Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med (2007) 2.54
Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med (2000) 2.54
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood (1999) 2.38
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy (2008) 2.18
Human intestinal mucosal mast cells: evaluation of fixation and staining techniques. J Clin Pathol (1981) 2.11
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A (2007) 2.02
Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature (2004) 1.91
Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol (2008) 1.83
Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res (2009) 1.82
Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther (2003) 1.81
Human lung mast cells: purification and characterization. J Immunol (1982) 1.78
The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol (2000) 1.76
Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol (2002) 1.76
Systemic mastocytosis. Annu Rev Med (2004) 1.74
Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol (1991) 1.69
The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis. Hepatology (2011) 1.67
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 1.66
Clonorchiasis and cholangiocarcinoma: etiologic relationship and imaging diagnosis. Clin Microbiol Rev (2004) 1.65
Peptide antibiotics in mast cells of fish. Nature (2001) 1.64
Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma (2005) 1.61
Aggressive surgical therapy for Klatskin tumors. Am J Surg (1993) 1.60
Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med (2000) 1.58
Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer (1995) 1.57
Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol (2008) 1.57
Structural and functional comparison of mast cells in the pregnant versus nonpregnant human uterus. Am J Obstet Gynecol (2006) 1.54
Mast cell population density, blood vessel density and histamine content in normal human skin. Br J Dermatol (1979) 1.53
Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem (1994) 1.47
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46
Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol (2006) 1.42
Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg (2004) 1.40
Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J Pathol (1997) 1.40
The human mast cell. J Allergy Clin Immunol (1997) 1.39
The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol (2012) 1.38
Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 1.26
Mast cells in innate immunity. J Allergy Clin Immunol (2004) 1.26
The mast cell in wound healing. Vet Dermatol (2001) 1.25
Mast cells: beyond IgE. J Allergy Clin Immunol (2003) 1.24
H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Lab Invest (2007) 1.24
Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy (2002) 1.23
Spiral CT of colon cancer: imaging features and role in management. Radiographics (2000) 1.22
Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4. Int Immunol (1996) 1.22
The H1 histamine receptor regulates allergic lung responses. J Clin Invest (2006) 1.21
Mast cell modulation of the vascular and lymphatic endothelium. Blood (2011) 1.19
Mechanisms of disease: chronic inflammation and cancer in the pancreas--a potential role for pancreatic stellate cells? Nat Clin Pract Gastroenterol Hepatol (2007) 1.19
Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest (2006) 1.18
The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol (1976) 1.18
DNA methylation in colorectal cancer--impact on screening and therapy monitoring modalities? Dis Markers (2007) 1.17
Intravital imaging of stromal cell dynamics in tumors. Curr Opin Genet Dev (2009) 1.16
H3-receptors control histamine release in human brain. J Neurochem (1988) 1.15
Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. Ann Surg (1997) 1.14
The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood (1994) 1.12
Distribution of mast cells in human dermis: development of a mapping technique. Br J Dermatol (1979) 1.11
Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum (1997) 1.10
Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol (2007) 1.10
Mast cells and angiogenesis in gastric carcinoma. Int J Exp Pathol (2010) 1.09
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut (2011) 1.08
Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One (2008) 1.07
Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol (1990) 1.07
The tumor microenvironment: the making of a paradigm. Cancer Microenviron (2009) 1.06
A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis (2008) 1.04
New concepts of histamine receptors and actions. Curr Allergy Asthma Rep (2003) 1.04
Mouse mast cell protease-1 is required for the enteropathy induced by gastrointestinal helminth infection in the mouse. Gastroenterology (2004) 1.02
Histamine release from gut mast cells from patients with inflammatory bowel diseases. Gut (1990) 1.01
Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol (2000) 1.01
Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets (2006) 1.00
Precancerous lesions of the biliary tree. J Surg Oncol Suppl (1993) 1.00
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol (2005) 1.00
Detection of isolated disseminated tumor cells in bone marrow and blood samples of patients with hepatocellular carcinoma. Arch Surg (2000) 0.99
Erlotinib in the treatment of advanced pancreatic cancer. Biologics (2008) 0.98
The roles of mast cells in anticancer immunity. Cancer Immunol Immunother (2012) 0.98
cIAP2 as a therapeutic target in colorectal cancer and other malignancies. Expert Opin Ther Targets (2009) 0.97
Underutilization of surgical resection in patients with localized pancreatic cancer. Ann Surg (2007) 0.97
Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer. J Med Assoc Thai (2008) 0.96
Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology (1990) 0.95
Molecular mechanisms of mast cell development. Immunol Allergy Clin North Am (2006) 0.95
Investigations of the 'active' edge of plaque psoriasis: vascular proliferation precedes changes in epidermal keratin. Br J Dermatol (1994) 0.95
Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci (2009) 0.94
Imaging of intrahepatic cholangiocarcinoma: 1. Peripheral cholangiocarcinoma. AJR Am J Roentgenol (1995) 0.93
Evaluation of endoscopic biopsy in gastric lesions with a special reference to the significance of mast cell density. Indian J Pathol Microbiol (2009) 0.92
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology (2011) 2.37
Human hepatic stem cell and maturational liver lineage biology. Hepatology (2011) 1.99
Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology (2006) 1.98
Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology (2006) 1.86
Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology (2012) 1.81
Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res (2006) 1.80
The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis. Hepatology (2011) 1.67
Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology (2009) 1.65
Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol (2006) 1.57
Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol (2008) 1.57
The biliary tree--a reservoir of multipotent stem cells. Nat Rev Gastroenterol Hepatol (2012) 1.50
cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. J Hepatol (2004) 1.46
Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem (2007) 1.43
Evaluation of differential gene expression by microarray analysis in small and large cholangiocytes isolated from normal mice. Liver Int (2003) 1.42
Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology (2005) 1.38
Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med (2012) 1.35
Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med (2009) 1.32
Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer (2012) 1.26
Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology (2004) 1.24
H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Lab Invest (2007) 1.24
gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res (2005) 1.23
Hedgehog activity, epithelial-mesenchymal transitions, and biliary dysmorphogenesis in biliary atresia. Hepatology (2011) 1.22
Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology (2002) 1.20
Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer. J Hepatol (2011) 1.20
Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol (2006) 1.20
Identification and functional characterization of TMEM16A, a Ca2+-activated Cl- channel activated by extracellular nucleotides, in biliary epithelium. J Biol Chem (2010) 1.19
The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. Am J Physiol Gastrointest Liver Physiol (2008) 1.18
Knockout of secretin receptor reduces large cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct ligation. Hepatology (2010) 1.17
Bile acid interactions with cholangiocytes. World J Gastroenterol (2006) 1.16
Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology (2002) 1.16
Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. Am J Physiol Gastrointest Liver Physiol (2007) 1.15
Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology (2002) 1.15
Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology (2012) 1.15
After damage of large bile ducts by gamma-aminobutyric acid, small ducts replenish the biliary tree by amplification of calcium-dependent signaling and de novo acquisition of large cholangiocyte phenotypes. Am J Pathol (2010) 1.13
The functional role of microRNAs in alcoholic liver injury. J Cell Mol Med (2014) 1.13
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol (2008) 1.12
Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor. Int J Cancer (2010) 1.12
Autophagy: highlighting a novel player in the autoimmunity scenario. J Autoimmun (2007) 1.12
The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis. J Hepatol (2005) 1.12
Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol (2012) 1.10
Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res (2004) 1.09
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut (2011) 1.08
Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am J Physiol Gastrointest Liver Physiol (2006) 1.08
Follicle-stimulating hormone increases cholangiocyte proliferation by an autocrine mechanism via cAMP-dependent phosphorylation of ERK1/2 and Elk-1. Am J Physiol Gastrointest Liver Physiol (2009) 1.08
Heterogeneity of the intrahepatic biliary epithelium. World J Gastroenterol (2006) 1.07
Alpha-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca(2+)- and PKC-dependent stimulation of cAMP. Hepatology (2004) 1.06
H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res (2009) 1.06
Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. Am J Physiol Gastrointest Liver Physiol (2003) 1.05
Differentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation. Hepatology (2009) 1.05
Cholangiocyte injury and ductopenic syndromes. Semin Liver Dis (2007) 1.05
Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol (2008) 1.05
Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis. Int J Cancer (2009) 1.04
Dopaminergic inhibition of secretin-stimulated choleresis by increased PKC-gamma expression and decrease of PKA activity. Am J Physiol Gastrointest Liver Physiol (2002) 1.04
Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol (2006) 1.03
Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology (2007) 1.03
Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol (2003) 1.03
Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci (2005) 1.02
Development and characterization of secretin-stimulated secretion of cultured rat cholangiocytes. Am J Physiol Gastrointest Liver Physiol (2003) 1.02
Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. Am J Physiol Gastrointest Liver Physiol (2005) 1.02
Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats. Gastroenterology (2002) 1.01
Cholangiocytes and blood supply. World J Gastroenterol (2006) 1.00
Leptin enhances cholangiocarcinoma cell growth. Cancer Res (2008) 1.00